[go: up one dir, main page]

RU2003111180A - POLYMER COMPOSITIONS FOR DELIVERY OF LEIPROLIDE WITH IMPROVED EFFICIENCY - Google Patents

POLYMER COMPOSITIONS FOR DELIVERY OF LEIPROLIDE WITH IMPROVED EFFICIENCY

Info

Publication number
RU2003111180A
RU2003111180A RU2003111180/15A RU2003111180A RU2003111180A RU 2003111180 A RU2003111180 A RU 2003111180A RU 2003111180/15 A RU2003111180/15 A RU 2003111180/15A RU 2003111180 A RU2003111180 A RU 2003111180A RU 2003111180 A RU2003111180 A RU 2003111180A
Authority
RU
Russia
Prior art keywords
composition
implant
polar aprotic
aprotic solvent
biocompatible
Prior art date
Application number
RU2003111180/15A
Other languages
Russian (ru)
Other versions
RU2271826C2 (en
Inventor
Ричард Л. ДАНН
Джон С. ГЭРРЕТТ
Хариш РАВИВАРАПУ
Бхагиа Л. ЧАНДРАШЕКАР
Original Assignee
Этрикс Лэборетриз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/711,758 external-priority patent/US6565874B1/en
Application filed by Этрикс Лэборетриз, Инк. filed Critical Этрикс Лэборетриз, Инк.
Publication of RU2003111180A publication Critical patent/RU2003111180A/en
Application granted granted Critical
Publication of RU2271826C2 publication Critical patent/RU2271826C2/en

Links

Claims (45)

1. Текучая композиция, пригодная для использования в качестве имплантата с регулируемой скоростью высвобождения, содержащая (а) биоразлагаемый термопластичный сложный полиэфир, который, по меньшей мере, в основном нерастворим в водной среде или в жидкости организма, (b) биосовместимый полярный апротонный растворитель, выбираемый из группы, состоящей из амида, сложного эфира, карбоната, кетона, простого эфира и сульфонила; где биосовместимый полярный апротонный растворитель совместим с водной средой или с жидкостью организма в пределах смешиваемости-диспергируемости, и (с) ацетат лейпролида.1. A flowable composition suitable for use as an implant with a controlled release rate, comprising (a) a biodegradable thermoplastic polyester that is at least substantially insoluble in an aqueous medium or body fluid, (b) a biocompatible polar aprotic solvent, selected from the group consisting of amide, ester, carbonate, ketone, ether and sulfonyl; where the biocompatible polar aprotic solvent is compatible with an aqueous medium or with body fluid within miscibility-dispersibility, and (c) leuprolide acetate. 2. Композиция по п.1, где биоразлагаемым термопластичным сложным полиэфиром являются полилактид, полигликолид, поликапролактон, их сополимер, их терполимер или любая их комбинация.2. The composition according to claim 1, where the biodegradable thermoplastic complex polyester are polylactide, polyglycolide, polycaprolactone, their copolymer, their terpolymer or any combination thereof. 3. Композиция по п.1, где биоразлагаемым термопластичным сложным полиэфиром являются полилактид, полигликолид, их сополимер, их терполимер или их комбинация.3. The composition according to claim 1, where the biodegradable thermoplastic complex polyester are polylactide, polyglycolide, their copolymer, their terpolymer or a combination thereof. 4. Композиция по п.1, где биоразлагаемым термопластичным сложным полиэфиром является 50/50 сополимер поли(DL-лактид-гликолид), имеющий концевую карбоксильную группу.4. The composition according to claim 1, where the biodegradable thermoplastic polyester is a 50/50 copolymer of poly (DL-lactide-glycolide) having a terminal carboxyl group. 5. Композиция по п.1, где биоразлагаемым термопластичным сложным полиэфиром является 75/25 сополимер поли(DL-лактид-гликолид), не имеющий концевой карбоксильной группы.5. The composition of claim 1, wherein the biodegradable thermoplastic polyester is a 75/25 poly (DL-lactide-glycolide) copolymer having no terminal carboxyl group. 6. Композиция по п.1, где биоразлагаемый термопластичный сложный полиэфир присутствует в количестве от приблизительно 30 до приблизительно 40 мас.% или от приблизительно 40 мас.% до приблизительно 50 мас.% от массы композиции.6. The composition according to claim 1, where the biodegradable thermoplastic complex polyester is present in an amount of from about 30 to about 40 wt.% Or from about 40 wt.% To about 50 wt.% By weight of the composition. 7. Композиция по п.1, где средняя молекулярная масса биоразлагаемого термопластичного сложного полиэфира находится в диапазоне от приблизительно 23000 до приблизительно 45000 или от приблизительно 15000 до приблизительно 24000.7. The composition according to claim 1, where the average molecular weight of the biodegradable thermoplastic complex polyester is in the range from about 23000 to about 45000, or from about 15000 to about 24000. 8. Композиция по п.1, где биосовместимым полярным апротонным растворителем являются N-метил-2-пирролидон, 2-пирролидон, N,N-диметилформамид, диметилсульфоксид, пропиленкарбонат, капролактам, триацетин или любая их комбинация.8. The composition according to claim 1, where the biocompatible polar aprotic solvent is N-methyl-2-pyrrolidone, 2-pyrrolidone, N, N-dimethylformamide, dimethyl sulfoxide, propylene carbonate, caprolactam, triacetin or any combination thereof. 9. Композиция по п.1, где биосовместимым полярным апротонным растворителем является N-метил-2-пирролидон.9. The composition according to claim 1, where the biocompatible polar aprotic solvent is N-methyl-2-pyrrolidone. 10. Композиция по п.1, где биосовместимый полярный апротонный растворитель присутствует в количестве от приблизительно 60 до приблизительно 70 мас.% от массы композиции.10. The composition according to claim 1, where the biocompatible polar aprotic solvent is present in an amount of from about 60 to about 70 wt.% By weight of the composition. 11. Композиция по п.1, где биосовместимый полярный апротонный растворитель присутствует в количестве от приблизительно 50 до приблизительно 60 мас.% от массы композиции.11. The composition according to claim 1, where the biocompatible polar aprotic solvent is present in an amount of from about 50 to about 60 wt.% By weight of the composition. 12. Композиция по п.1, где ацетат лейпролида присутствует в количестве от приблизительно 2 до приблизительно 4 мас.% от массы композиции.12. The composition according to claim 1, where the leuprolide acetate is present in an amount of from about 2 to about 4 wt.% By weight of the composition. 13. Композиция по п.1, где ацетат лейпролида присутствует в количестве от приблизительно 4 до приблизительно 8 мас.% от массы композиции.13. The composition according to claim 1, where the leuprolide acetate is present in an amount of from about 4 to about 8 wt.% By weight of the composition. 14. Композиция по п.1, полученная в виде подкожно инъецируемой системы доставки.14. The composition according to claim 1, obtained in the form of a subcutaneously injectable delivery system. 15. Композиция по п.14, имеющая объем от приблизительно 0,20 до приблизительно 0,40 мл.15. The composition of claim 14, having a volume of from about 0.20 to about 0.40 ml. 16. Композиция по п.14, имеющая объем от приблизительно 0,30 до приблизительно 0,50 мл.16. The composition of claim 14, having a volume of from about 0.30 to about 0.50 ml. 17. Композиция по п.14, составленная для введения в организм приблизительно один раз в месяц.17. The composition of claim 14, formulated for administration to the body approximately once a month. 18. Композиция по п.14, составленная для введения в организм приблизительно один раз в три месяца.18. The composition of claim 14, formulated for administration to the body approximately every three months. 19. Композиция по п.14, составленная для введения в организм от приблизительно одного раза в четыре месяца до приблизительно одного раза в шесть месяцев.19. The composition of claim 14, formulated for administration to the body from about once every four months to about once every six months. 20. Способ получения текучей композиции, предназначенной для использования в качестве имплантата с регулируемой скоростью высвобождения лекарственного средства, включающий стадию смешивания в любом порядке: (а) биоразлагаемого термопластичного сложного полиэфира, который, по меньшей мере, в значительной степени нерастворим в водной среде или в жидкости организма, (b) биосовместимого полярного апротонного растворителя, выбираемого из группы, состоящей из амида, сложного эфира, карбоната, кетона, простого эфира и сульфонила, где биосовместимый полярный апротонный растворитель совместим с водной средой или с жидкостью организма в пределах смешиваемости-диспергируемости, и (с) ацетата лейпролида, где смешивание производят в течение достаточного периода времени, эффективного для получения текучей композиции, предназначенной для использования в качестве имплантата с регулируемой скоростью высвобождения лекарственного средства.20. A method of producing a fluid composition intended for use as an implant with a controlled release rate of a drug, comprising the step of mixing in any order: (a) a biodegradable thermoplastic polyester that is at least substantially insoluble in an aqueous medium or in body fluids, (b) a biocompatible polar aprotic solvent selected from the group consisting of amide, ester, carbonate, ketone, ether and sulfonyl, where the biocompatible The polar aprotic solvent is compatible with the aqueous medium or body fluid within miscibility-dispersibility, and (c) leuprolide acetate, where the mixing is carried out for a sufficient period of time, effective to obtain a fluid composition intended for use as an implant with a controlled release rate medicinal product. 21. Способ по п.20, где биосовместимый термопластичный сложный полиэфир и биосовместимый полярный апротонный растворитель смешивают друг с другом с получением смеси, а затем данную смесь смешивают с ацетатом лейпролида с получением текучей композиции.21. The method according to claim 20, where the biocompatible thermoplastic polyester and the biocompatible polar aprotic solvent are mixed with each other to obtain a mixture, and then this mixture is mixed with leuprolide acetate to obtain a flowable composition. 22. Применение биоразлагаемого термопластичного сложного полиэфира, биосовместимого полярного апротонного растворителя и лейпролида для получения композиции, которая способна в организме пациента образовывать in situ биоразлагаемый имплантат при инъецировании и с образованием твердого биоразлагаемого имплантата, где композиция содержит эффективное количество биоразлагаемого термопластичного сложного полиэфира, который, по меньшей мере, в значительной степени нерастворим в водной среде или в жидкости организма, эффективное количество биосовместимого полярного апротонного растворителя, выбираемого из группы, состоящей из амида, сложного эфира, карбоната, кетона, простого эфира и сульфонила, причем биосовместимый полярный апротонный растворитель совместим с водной средой или с жидкостью организма в пределах смешиваемости-диспергируемости, и эффективное количество ацетата лейпролида.22. The use of a biodegradable thermoplastic polyester, a biocompatible polar aprotic solvent and leuprolide to obtain a composition that is capable of forming an in situ biodegradable implant in the patient’s body upon injection and with the formation of a solid biodegradable implant, where the composition contains an effective amount of biodegradable thermoplastic polyester, which, according to at least substantially insoluble in the aquatic environment or in body fluids, effective amounts a biocompatible polar aprotic solvent selected from the group consisting of amide, ester, carbonate, ketone, ether and sulfonyl, wherein the biocompatible polar aprotic solvent is compatible with the aqueous medium or body fluid within miscibility-dispersibility, and an effective amount of leuprolide acetate . 23. Применение по п.22, где пациентом является человек.23. The use of claim 22, wherein the patient is a human. 24. Применение по п.22, где твердый имплантат высвобождает эффективное количество лейпролида по мере того, как твердый имплантат претерпевает биоразложение в организме пациента.24. The use of claim 22, wherein the solid implant releases an effective amount of leuprolide as the solid implant undergoes biodegradation in the patient. 25. Применение по п.22, где твердый биоразлагаемый имплантат прилипает к ткани в организме пациента.25. The application of item 22, where the solid biodegradable implant adheres to the tissue in the patient's body. 26. Применение по п.22, где твердый биоразлагаемый имплантат высвобождает эффективное количество ацетата лейпролида в результате диффузии, эрозии или комбинации диффузии и эрозии по мере того, как твердый имплантат претерпевает биоразложение в организме пациента.26. The application of claim 22, wherein the solid biodegradable implant releases an effective amount of leuprolide acetate as a result of diffusion, erosion, or a combination of diffusion and erosion as the solid implant undergoes biodegradation in the patient. 27. Применение по п.22, где пациент страдает от рака, а композиция полезна при лечении рака.27. The use of claim 22, wherein the patient suffers from cancer and the composition is useful in the treatment of cancer. 28. Применение по п.27, где раком является рак предстательной железы.28. The use of claim 27, wherein the cancer is prostate cancer. 29. Применение по п.28, где пациентом является человек.29. The application of claim 28, wherein the patient is a human. 30. Применение по п.22, где имплантат способен уменьшать уровни LHRH (рилизинг-фактора лютеинизирующего гормона) в организме пациента вследствие присутствия эффективного количества композиции.30. The application of item 22, where the implant is able to reduce the levels of LHRH (releasing factor luteinizing hormone) in the patient's body due to the presence of an effective amount of the composition. 31. Применение по п.30, где уменьшение уровней LHRH полезно при лечении эндометриоза.31. The application of clause 30, where the reduction of LHRH levels is useful in the treatment of endometriosis. 32. Набор, включающий (а) первый контейнер, содержащий композицию, которая содержит биоразлагаемый термопластичный сложный полиэфир, который, по меньшей мере, в значительной степени нерастворим в водной среде или в жидкости организма, и биосовместимый полярный апротонный растворитель, выбираемый из группы, состоящей из амида, сложного эфира, карбоната, кетона, простого эфира и сульфонила, где биосовместимый полярный апротонный растворитель совместим с водной средой или с жидкостью организма в пределах смешиваемости-диспергируемости, и (b) второй контейнер, содержащий ацетат лейпролида.32. A kit comprising (a) a first container containing a composition that contains a biodegradable thermoplastic polyester that is at least substantially insoluble in an aqueous medium or body fluid, and a biocompatible polar aprotic solvent selected from the group consisting of from an amide, ester, carbonate, ketone, ether and sulfonyl, where the biocompatible polar aprotic solvent is compatible with the aqueous medium or body fluid within miscibility-dispersibility, and (b) a second container containing leuprolide acetate. 33. Набор по п.32, где первым контейнером является шприц.33. The kit of claim 32, wherein the first container is a syringe. 34. Набор по п.32, где вторым контейнером является шприц.34. The kit of claim 32, wherein the second container is a syringe. 35. Набор по п.32, где ацетат лейпролида подвергнут лиофилизации.35. The kit of claim 32, wherein the leuprolide acetate is lyophilized. 36. Набор по п.32, дополнительно включающий инструкции.36. The kit of claim 32, further comprising instructions. 37. Набор по п.32, где первый контейнер можно присоединить ко второму контейнеру.37. The kit according to p, where the first container can be attached to the second container. 38. Набор по п.32, где первый контейнер и второй контейнер, каждый, имеют конфигурацию, позволяющую им быть непосредственно соединенными друг с другом.38. The kit according to p, where the first container and the second container, each, have a configuration that allows them to be directly connected to each other. 39. Твердый имплантат, содержащий (а) биосовместимый термопластичный сложный полиэфир, который, по меньшей мере, в основном нерастворим в водной среде или в жидкости организма, и (b) ацетат лейпролида, где твердый имплантат образован твердой или студенистой микропористой матрицей, причем матрица представляет собой сердцевину, окруженную оболочкой.39. A solid implant comprising (a) a biocompatible thermoplastic polyester that is at least substantially insoluble in an aqueous medium or body fluid, and (b) leuprolide acetate, where the solid implant is formed by a solid or gelatinous microporous matrix, the matrix represents the core surrounded by a shell. 40. Твердый имплантат по п.39, дополнительно содержащий биосовместимый органический растворитель, который совместим с водной средой или с жидкостью организма в пределах смешиваемости-диспергируемости и который растворяет термопластичный сложный полиэфир.40. The solid implant of claim 39, further comprising a biocompatible organic solvent that is compatible with the aqueous medium or body fluid within miscibility-dispersibility and which dissolves the thermoplastic polyester. 41. Твердый имплантат по п.40, где количество биосовместимого органического растворителя минимально.41. The solid implant of claim 40, wherein the amount of the biocompatible organic solvent is minimal. 42. Твердый имплантат по п.39, где количество биосовместимого органического растворителя уменьшается с течением времени.42. The solid implant of claim 39, wherein the amount of the biocompatible organic solvent decreases over time. 43. Твердый имплантат по п.39, где сердцевина содержит поры диаметром от приблизительно 1 до приблизительно 1000 мкм.43. The solid implant according to § 39, where the core contains pores with a diameter of from about 1 to about 1000 microns. 44. Твердый имплантат по п.39, где оболочка содержит поры меньшего диаметра по сравнению с диаметрами пор в сердцевине.44. The solid implant according to § 39, where the shell contains pores of smaller diameter compared with the diameters of the pores in the core. 45. Твердый имплантат по п.39, где поры в оболочке имеют такой размер, что оболочка функционально является непористой по сравнению с сердцевиной.45. The solid implant according to § 39, where the pores in the shell are of such a size that the shell is functionally non-porous compared to the core.
RU2003111180/15A 2000-09-21 2001-09-21 Resin composition for leuprolide delivery of improved effectiveness RU2271826C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66617400A 2000-09-21 2000-09-21
US09/666,174 2000-09-21
US09/711,758 2000-11-13
US09/711,758 US6565874B1 (en) 1998-10-28 2000-11-13 Polymeric delivery formulations of leuprolide with improved efficacy

Publications (2)

Publication Number Publication Date
RU2003111180A true RU2003111180A (en) 2004-08-27
RU2271826C2 RU2271826C2 (en) 2006-03-20

Family

ID=27099398

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003111180/15A RU2271826C2 (en) 2000-09-21 2001-09-21 Resin composition for leuprolide delivery of improved effectiveness

Country Status (26)

Country Link
US (8) US6565874B1 (en)
EP (3) EP1586309B3 (en)
JP (4) JP2004510807A (en)
KR (1) KR100831113B1 (en)
CN (2) CN101669900B (en)
AT (2) ATE458469T3 (en)
AU (4) AU2001292931B2 (en)
BR (1) BRPI0114069B8 (en)
CA (1) CA2436275C (en)
CY (3) CY1106045T1 (en)
CZ (1) CZ303134B6 (en)
DE (2) DE60141421D1 (en)
DK (3) DK1586309T6 (en)
ES (3) ES2341777T7 (en)
HU (1) HU228386B1 (en)
IL (2) IL155006A0 (en)
IS (1) IS6794A (en)
MX (1) MXPA03002552A (en)
NZ (1) NZ525210A (en)
PL (1) PL226346B1 (en)
PT (3) PT1322286E (en)
RU (1) RU2271826C2 (en)
SI (1) SI1322286T1 (en)
SK (1) SK287528B6 (en)
WO (1) WO2002030393A2 (en)
ZA (1) ZA200302944B (en)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
ATE322513T1 (en) * 2000-08-07 2006-04-15 Wako Pure Chem Ind Ltd LACTIC ACID POLYMER AND METHOD FOR THE PRODUCTION THEREOF
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
ATE528014T1 (en) 2002-06-07 2011-10-15 Dyax Corp POLYPEPTIDE WITH MODIFIED KUNITZ DOMAINS
CN1485072A (en) * 2002-09-28 2004-03-31 Coix seed oil soft capsule for curing prostate diseases and the application thereof
CA2518791A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell-schedule dependent anticancer agents
DE602004015744D1 (en) * 2003-03-14 2008-09-25 Debio Rech Pharma Sa SUBCUTANEOUS ADMINISTRATION SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND USE FOR THE TREATMENT OF FAILURE OF THE CHOLINERGEN NERVOUS SYSTEM
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
ES2447423T3 (en) * 2003-08-29 2014-03-12 Dyax Corp. Poly-pegylated protease inhibitors
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
EP1703915A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
JP2007517913A (en) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド Method for treating acute myocardial infarction by administering calcitonin gene-related peptide and composition containing calcitonin gene-related peptide
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
BRPI0506793A (en) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp Obesity or diabetes treatment methods using nt-4/5
JP2007526085A (en) * 2004-03-02 2007-09-13 ナノセラピューティクス・インコーポレイテッド Compositions for repairing bone and methods for preparing and using such compositions
JP2007526942A (en) * 2004-03-03 2007-09-20 コモンウエルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Biocompatible polymer composition for two-stage or multi-stage curing
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
AU2005271700B2 (en) 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
EP1804751A2 (en) * 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
US20090092650A1 (en) * 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
US20060189958A1 (en) * 2005-02-21 2006-08-24 Talton James D Inverted cannula for use in reconstituting dry material in syringes
TWI334363B (en) * 2005-06-07 2010-12-11 Saint Gobain Ceramics A catalyst carrier
WO2007011340A1 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
MX2008001638A (en) 2005-08-08 2009-02-24 Cytyc Corp Tumescent skin spacing method.
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8068991B2 (en) * 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
WO2007082726A2 (en) * 2006-01-17 2007-07-26 Medigene Ag Flowable leuprolide-containing composition for treating inflammation-mediated neurodegenerative diseases
DK1984009T3 (en) 2006-01-18 2013-01-28 Qps Llc Pharmaceutical compositions with improved stability
CN101400367A (en) * 2006-02-02 2009-04-01 瑞纳神经科学公司 Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
DK1989220T3 (en) 2006-02-02 2012-04-02 Trimeris Inc HIV fusion inhibitor peptides with enhanced biological properties
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
US8013061B2 (en) 2006-03-08 2011-09-06 The University Of North Carolina At Chapel Hill Polyester based degradable materials and implantable biomedical articles formed therefrom
JP5231412B2 (en) * 2006-07-11 2013-07-10 キューピーエス リミテッド ライアビリティ カンパニー Pharmacological composition for delivering peptides by sustained release
US8076448B2 (en) * 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
ZA200902587B (en) * 2006-11-09 2010-06-30 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
EP2086502B1 (en) * 2006-11-09 2013-04-17 Alcon Research, Ltd. Punctal plug comprising a water-insoluble polymeric matrix
CN101563068B (en) * 2006-12-18 2013-03-20 武田药品工业株式会社 Sustained release composition and its preparation method
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
DK3660073T3 (en) 2007-02-15 2023-09-18 Tolmar International Ltd POLY(LACTIDE-CO-GLYCOLIDE) WITH LOW BLASTING
JP2010523564A (en) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド Novel formulations for delivery of antiviral peptide therapeutics
CA2687979C (en) * 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
AU2008303919A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of angiotensin II as a therapeutic agent in the treatment of eg S. pneumoniae infection
CN101874038A (en) * 2007-09-25 2010-10-27 特里梅里斯公司 Synthetic method of therapeutic anti-HIV peptide
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US20090112193A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices that utilize photolyzable nitric oxide donors
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8828354B2 (en) 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US20090264478A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Sulfasalazine formulations in a biodegradable polymer carrier
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
EP2293784B1 (en) 2008-06-03 2016-04-13 Indivior UK Limited Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
CN102112107A (en) * 2008-06-03 2011-06-29 托马医疗科技公司 Controlled release copolymer formulation with improved release kinetics
PT2291174E (en) * 2008-06-03 2015-05-20 Tolmar Therapeutics Inc Flowable composition comprising biocompatible oligomer-polymer compositions
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
CN101653422B (en) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 Risperidone slow-release microsphere, preparation method and application thereof
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US9161903B2 (en) 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8980317B2 (en) 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
US8469779B1 (en) 2009-01-02 2013-06-25 Lifecell Corporation Method for debristling animal skin
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8758791B2 (en) * 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2390439B1 (en) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP2394664B1 (en) 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
SMT202100679T1 (en) 2010-05-31 2022-01-10 Laboratorios Farmaceuticos Rovi S A Compositions for injectable in-situ biodegradable implants
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9364518B2 (en) * 2010-06-24 2016-06-14 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
US9301946B2 (en) 2010-12-03 2016-04-05 Warsaw Orthopedic, Inc. Clonidine and GABA compounds in a biodegradable polymer carrier
CA2822854C (en) 2010-12-29 2020-01-07 Medincell Biodegradable drug delivery compositions
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8637067B1 (en) 2011-03-10 2014-01-28 Lifecell Corporation Elastic tissue matrix derived hydrogel
BR112013026200A2 (en) 2011-04-14 2019-08-27 Lifecell Corp method for preparing a fabric matrix, and tissue matrix composition
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9089523B2 (en) 2011-07-28 2015-07-28 Lifecell Corporation Natural tissue scaffolds as tissue fillers
KR101494594B1 (en) 2011-08-30 2015-02-23 주식회사 종근당 Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
EP3501558B1 (en) 2011-12-20 2020-11-25 LifeCell Corporation Flowable tissue products
EP3549615B1 (en) 2011-12-20 2020-12-16 LifeCell Corporation Sheet tissue products
EP3797801A1 (en) 2012-01-24 2021-03-31 LifeCell Corporation Elongated tissue matrices
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
EP2841116A1 (en) 2012-04-24 2015-03-04 Lifecell Corporation Flowable tissue matrices
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
EP2872191B1 (en) 2012-07-13 2019-08-07 LifeCell Corporation Methods for improved treatment of adipose tissue
CA2885327A1 (en) 2012-09-26 2014-04-03 Lifecell Corporation Processed adipose tissue
KR101586791B1 (en) 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014123703A1 (en) 2013-02-06 2014-08-14 Lifecell Corporation Methods for localized modification of tissue products
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
MX378264B (en) 2015-08-03 2025-03-10 Tolmar International Ltd Liquid polymer delivery system for extended administration of drugs
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CA3005313C (en) * 2015-11-16 2024-01-09 Evonik Rohm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
EP3463500A1 (en) 2016-06-03 2019-04-10 LifeCell Corporation Methods for localized modification of tissue products
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2018102700A1 (en) * 2016-12-01 2018-06-07 Pinscreen, Inc. Photorealistic facial texture inference using deep neural networks
US11045583B2 (en) 2016-12-22 2021-06-29 Lifecell Corporation Devices and methods for tissue cryomilling
AU2018217064A1 (en) 2017-01-31 2019-08-08 Veru Inc. Compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR102412628B1 (en) * 2017-08-28 2022-06-23 차의과학대학교 산학협력단 Method for manufacturing sustained release microsphere containing leuprolide prepared by electrospraying
RU2020104475A (en) * 2017-09-27 2021-08-02 Новел Фарма Инк. PALMITIC ACID CONJUGATED PROLONGED GnRH DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT
EP3697460A1 (en) 2017-10-18 2020-08-26 LifeCell Corporation Adipose tissue products and methods of production
US11123375B2 (en) 2017-10-18 2021-09-21 Lifecell Corporation Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
CA3075106A1 (en) 2017-10-19 2019-04-25 Lifecell Corporation Flowable acellular tissue matrix products and methods of production
US11246994B2 (en) 2017-10-19 2022-02-15 Lifecell Corporation Methods for introduction of flowable acellular tissue matrix products into a hand
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
KR102522654B1 (en) * 2017-12-18 2023-04-17 포시 파마슈티컬스 컴퍼니 리미티드 Pharmaceutical composition with selected release period
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
PE20210047A1 (en) 2018-06-12 2021-01-08 Farm Rovi Lab Sa INJECTABLE COMPOSITION
US20220040201A1 (en) * 2018-09-25 2022-02-10 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
CN109498852B (en) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 Biodegradable material for treating orthopedic diseases and application thereof
US20200330547A1 (en) * 2019-04-22 2020-10-22 Tolmar International Limited Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
MX2021014540A (en) 2019-05-27 2022-04-12 Tolmar International Ltd COMPOSITIONS OF LEUPROLIDE ACETATE AND METHODS OF USING SAME TO TREAT BREAST CANCER.
CA3142151A1 (en) 2019-05-30 2020-12-03 Lifecell Corporation Biologic breast implant
CN111214643A (en) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 Octreotide composition based on subcutaneous gel sustained release, preparation method and application
JP7542661B2 (en) 2020-06-30 2024-08-30 チョン クン ダン ファーマシューティカル コーポレーション Injectable compositions containing GNRH derivatives
US20230355511A1 (en) 2020-09-30 2023-11-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US11908233B2 (en) 2020-11-02 2024-02-20 Pinscreen, Inc. Normalization of facial images using deep neural networks
KR102742097B1 (en) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 Systems and methods for mixing syringe valve assemblies
JP2024515220A (en) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー Implantable devices for the sustained release of macromolecular drug compounds - Patents.com
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
KR102386163B1 (en) 2021-12-03 2022-04-14 (주)인벤티지랩 Microparticles containing leuprolide and manufacturing method thereof
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector
KR20240079177A (en) 2022-11-28 2024-06-04 동국제약 주식회사 Sustained-release pharmaceutical composition capable of forming an in-situ implant and manufacturing the same
WO2025008759A1 (en) * 2023-07-05 2025-01-09 Tolmar International Limited Polymeric leuprolide acetate formulations
WO2025124422A1 (en) * 2023-12-13 2025-06-19 长春金赛药业有限责任公司 In-situ subcutaneous implantable female hormone modulation composition, preparation method therefor, and use thereof
US20250248927A1 (en) * 2024-02-01 2025-08-07 Celanese Eva Performance Polymers Llc Implantable Device for Release of Gonadotropin-Releasing Hormone Agonist or Antagonist
WO2025196632A1 (en) 2024-03-22 2025-09-25 Tolmar International Limited Systems and methods for mixing syringe valve assemblies and syringe formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284417A (en) * 1963-11-13 1966-11-08 Union Carbide Corp Process for the preparation of lactone polyesters
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4040420A (en) * 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
JP2551756B2 (en) * 1985-05-07 1996-11-06 武田薬品工業株式会社 Polyoxycarboxylic acid ester and method for producing the same
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2988633B2 (en) 1990-03-16 1999-12-13 三和生薬株式会社 Hair growth / hair restorer
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3277342B2 (en) * 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RU2084458C1 (en) * 1993-05-27 1997-07-20 Институт высокомолекулярных соединений РАН Decapeptide showing antitumor activity
WO1995027481A1 (en) * 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747637A (en) 1995-09-07 1998-05-05 Mitsui Toatsu Chemicals, Inc. Bioabsorbable polymer and process for preparing the same
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
PL189289B1 (en) * 1996-02-02 2005-07-29 Alza Corp Method for preparation of an implanted system used to prolonged delivery of active substance
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
JPH10279499A (en) * 1997-04-04 1998-10-20 Takeda Chem Ind Ltd Preparation applicable to uterine mucosa
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
KR100321854B1 (en) 1998-12-30 2002-08-28 동국제약 주식회사 Long-term sustained-release microspheres containing luteinizing hormone releasing hormone homologues and a method of producing the same
WO2001019887A1 (en) * 1999-09-10 2001-03-22 Mitsui Chemicals, Inc. Polyurethane resin with degradability
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2005059003A1 (en) 2003-12-15 2005-06-30 The Children's Hospital Of Philadelphia Novel polyesters

Similar Documents

Publication Publication Date Title
RU2003111180A (en) POLYMER COMPOSITIONS FOR DELIVERY OF LEIPROLIDE WITH IMPROVED EFFICIENCY
ES2240236T3 (en) COMPOSITION OF BIODEGRADABLE POLYMER.
JP6061823B2 (en) Leuprolide polymer delivery formulation with improved efficacy
JP2004510807A5 (en)
RU2012157244A (en) LIQUID INJECTION COMPOSITIONS, INCLUDING BUPRENORPHIN
US7160551B2 (en) Injectable system for controlled drug delivery
PL192270B1 (en) Liquid polymeric compositions for controlled release of bioactive substances
JP2002537221A (en) Moldable solid delivery system
MX2014015902A (en) Biodegradable drug delivery for hydrophobic compositions.
AU2001292931A1 (en) Polymeric delivery formulations of leuprolide with improved efficacy
JP2008524235A5 (en)
HK1139596B (en) Polymeric delivery formulations of leuprolide with improved efficacy